LetterLetters to the Editor

Reply: The Need for Prudence When Using 18F-FDG PET as a Reference Standard for Lymphoma Detection

Sue C. Kaste, Monika Metzger and Barry L. Shulkin
Journal of Nuclear Medicine August 2017, 58 (8) 1355; DOI: https://doi.org/10.2967/jnumed.117.190652

REPLY: Thank you for allowing us to respond to Drs. Adams and Kwee, who caution readers about the utility of 18F-FDG in this letter, as they have done in many others (1–6). We thank them for their comments on our article (7) and appreciate their perspective on 18F-FDG, which, though imperfect, remains internationally regarded as the functional imaging agent of choice for patients with lymphoma.

Footnotes

  • Published online Apr. 27, 2017.

REFERENCES

  1. 1.
    1. Adams HJ,
    2. Kwee TC
    . Interim PET-CT scan in advanced Hodgkin’s lymphoma [letter]. N Engl J Med. 2016;375:999.
  2. 2.
    1. Adams HJ,
    2. Kwee TC
    . A negative 18F-FDG-PET scan can never exclude residual disease [letter]. Nucl Med Commun. 2016;37:102–103.
  3. 3.
    1. Adams HJ,
    2. Kwee TC
    . Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin’s lymphoma [letter]. Lancet Haematol. 2017;4:e63–e64.
  4. 4.
    1. Adams HJA,
    2. Kwee TC
    . Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma [letter]. J Clin Oncol. 2015;33:1217–1218.
  5. 5.
    1. Adams HJA,
    2. Kwee TC
    . In regard to Ceriani et al. [letter]. Int J Radiat Oncol Biol Phys. 2017;97:869–870.
  6. 6.
    1. Adams HJ,
    2. Kwee TC
    . Neither posttreatment PET/CT nor interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma [letter]. J Nucl Med. 2017;58:684–685.
  7. 7.
    1. Kaste SC,
    2. Snyder SE,
    3. Metzger ML,
    4. et al
    . Comparison of 11C-methionine and 18F-FDG PET/CT for staging and follow-up of pediatric lymphoma. J Nucl Med. 2017;58:419–424.